About

Tissue Regenix Group plc is a pioneering, international medical technology company, leading the development of regenerative products to make replacement body parts using biological (human & animal) tissues

About

Tissue Regenix Group plc is a pioneering, international medical technology company, leading the development of regenerative products to make replacement body parts using biological (human & animal) tissues

Our Story

Commercialising academic research in regenerative medicine

The company’s patented decellularisation (‘dCELL®’) Technology removes DNA and other cellular material from tissue leaving intact an inert acellular matrix upon which the patients cells can repopulate. 

The potential applications of dCELL® are diverse and address critical clinical needs such as; wound care, heart valve replacement and knee repair. 

Spun out of the University of Leeds in 2006, Tissue Regenix commercialise upon research undertaken by our higher education and research partners around the world. Tissue Regenix listed on the Alternative Investment Market (AIM) on the London Stock Exchange in 2010, before opening the first subsidiary office Tissue Regenix Woundcare, Inc. in San Antonio, Texas in 2012. 

In early 2016, Tissue Regenix entered its first joint venture establishing GBM-V , a Tissue Bank in Rostock, Germany, granting them the first licence for the production of dCELL® heart valves, and strengthening its presence within Europe.     

US $6.47BN

Expected value of the Global Regenerative Medicine Market by 2019

Our Technology

 dCELL®  gentle, efficient, effective — and powerful

The dCELL® process involves the creation of biological scaffolds which are essentially inert. By removing DNA and cellular material from biological tissues,  the patient's cells can repopulate and colonize creating new, like for like tissue, which is recognized and accepted by the body, significantly reducing the risk of rejection, and stimulating a natural healing process. 

What is Regenerative Medicine?

Regenerative medicine is an innovative and expanding field, researching the potential of tissue engineering and molecular biology to offer a natural recovery by triggering a response through the body's own cells. With the demand for less invasive, longer lasting treatment modalities, regenerative medicine is an increasingly important approach as it removes the need for synthetic (plastic or metal) replacements, reduces the risk of rejection, while offering the potential for less time-consuming and potentially more cost-effective treatments.

dCELL Technology

Our Plan

Improve quality of life for patient's

Tissue Regenix is developing and commercializing a range of medical devices and treatments based on our patented dCELL® process. We have established operations in the US and UK to target multi-billion dollar global healthcare markets.
Tissue Regenix is currently focusing on three core treatment areas, through its TRX Wound Care, TRX Cardiac and TRX Orthopaedics divisions, working with our research partners, including the University of Leeds, Brazil’s Pontifical University of Parana, and NHSBT, to commercialise the intellectual property rights they generate. 

Our Team

A senior team, experienced in commercialising the academic research conducted by our partners around the world.

    • Antony Odell was appointed CEO of Tissue Regenix in October 2008 and has led its growth from a small privately held spin-out to the present time. He has over 30 year’s commercial experience in the medical technology sector. Antony has a strong corporate sector background having worked for Critikon, Johnson & Johnson Medical and was European Business Director for its Vascular Access franchise, General Manager (UK & Ireland) for Fresenius (Critical Care & Diagnostics) and International Knee Manager for Stryker (Howmedica International). Antony was also VP- Medical for BTG when the company was involved in early stage technology commercialisation and was CEO for a Scottish NHS cardiovascular device spin-out, Tayside Flow Technologies Ltd (now Vascular Flow Technologies Ltd).

    • Paul joined Tissue Regenix plc as CFO in January 2017, having spent the largest part of his career in businesses undergoing significant change. His experience includes listed and private equity owned businesses in the FMCG, food, pharmaceutical and healthcare technology sectors.  Recent experience includes the sale of Fletchers Bakeries to Finsbury Food Group plc, part of which was the successful reverse listing of Fletchers on AIM. Previous employment includes Northern Foods plc, Mallinckrodt Inc., Bakkavor and Tunstall Healthcare.

    • Andrea Rausch was appointed as Business Development Manager in the Tissue Regenix Cardiac team in August 2012. Andrea joined Tissue Regenix from Sorin Group, a global medical device company and a leader in the development of medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.

      For two years, she was Global Marketing Manager at Sorin for the Perceval Programme, a new treatment option for aortic valve disease, having been Business Line Leader and Strategic Sales and Marketing Manager of the Heart Valves team in Germany for five years before this.

    • Joel Pickering joined Tissue Regenix Wound Care Inc. in October 2015 to assume the leadership of the US marketing organization. Joel moved into the position of President in January 2017 and now  guides the commercial marketing strategy for DermaPure® and SurgiPure® in the United States.

      Joel brings a wealth of wound care marketing experience dating back to 1996 with such companies as J & J Medical, Lifecell, Convatec and KCI.  Prior to joining Tissue Regenix, Joel served as VP of Marketing and Communications for Novation with responsibility for driving Novation growth in the US.

      Through his time in the wound care category, Joel has launched several new brands and driven many established brands to category leading shares through a combination of vision, communication and team leadership.

    • Peter Hamer was appointed as Business Development Manager of the Tissue Regenix Orthopaedics division in early 2013. Peter is responsible for leading the development of sales and marketing activity of the Group’s Orthopaedics product range.

      Peter has over 25 years sales and marketing experience in medical devices, 15 years of which have been in various Senior Management Commercial roles within Biomet and Allergan. Prior to joining Tissue Regenix Peter worked at Corin Group, leading all export sales territories through third party distributors as well as heading up the Corin Group UK subsidiary sales and marketing business.

    • Mike Izon joined as Head of QA/RA and Clinical at Tissue Regenix in November 2014. With a background in pharmaceutical products and medical devices, Mike has worked over the last 10 years as a consultant, trainer and assessor for the certification and registration of medical devices. Having worked extensively with early stage medical device development companies, Mike has also worked with household names such as Procter & Gamble, Bausch & Lomb and Carl Zeiss Medical to achieve worldwide market clearance for a range of products and technologies

    • Tony Hewitt joined Tissue Regenix in June 2014 and was subsequently appointed UK Operations Director in January 2015. Tony has considerable operational experience, having worked for over 20 years within the medical device and pharmaceutical sectors. Prior to working at Tissue Regenix he held a variety of technical, manufacturing and operational management positions with Sanofi Aventis, Smith & Nephew and Covidien.

The Board

A board team, made up of experienced experts in the healthcare and business industries.

    • John Samuel joined Tissue Regenix as Executive Chairman in March 2008. John qualified as a Chartered Accountant with Price Waterhouse and has held a number of senior finance positions in industry, including as Financial Director of Whessoe plc and Ellis & Everard plc. He was formerly the CEO of the Molnlycke Health Care Group, a global provider of single use surgical and wound care products to the healthcare sector. Until January 2010 he was a Partner with Apax Partners LLP. John is also Chairman of Vernacare Group ltd and Xeros Cleaning Technologies. 

    • Antony Odell was appointed CEO of Tissue Regenix in October 2008 and has led its growth from a small privately held spin-out to the present time. He has over 30 year’s commercial experience in the medical technology sector. Antony has a strong corporate sector background having worked for Critikon, Johnson & Johnson Medical and was European Business Director for its Vascular Access franchise, General Manager (UK & Ireland) for Fresenius (Critical Care & Diagnostics) and International Knee Manager for Stryker (Howmedica International). Antony was also VP- Medical for BTG when the company was involved in early stage technology commercialisation and was CEO for a Scottish NHS cardiovascular device spin-out, Tayside Flow Technologies Ltd (now Vascular Flow Technologies Ltd).

    • Paul joined Tissue Regenix plc as CFO in January 2017, having spent the largest part of his career in businesses undergoing significant change. His experience includes listed and private equity owned businesses in the FMCG, food, pharmaceutical and healthcare technology sectors.  Recent experience includes the sale of Fletchers Bakeries to Finsbury Food Group plc, part of which was the successful reverse listing of Fletchers on AIM. Previous employment includes Northern Foods plc, Mallinckrodt Inc., Bakkavor and Tunstall Healthcare.

    • Alan Miller is the Chief Investment Officer and a Founding Partner of SCM Direct, an online wealth management company. He was formerly the Chief Investment Officer and founding shareholder of New Star Asset Management from early 2001 until early 2007. Prior to that, Alan was a Director at Jupiter Asset Management in charge of their specialist high performance division between 1994 and 2000.  He is also a qualified accountant and alumni of the London Business School.


    • Randeep Grewal is a fund manager at Trium Capital LLP. He has 17 years of experience in institutional investing having worked at F&C Asset Management, ICAP Equities and Tudor Capital, where he spent 10 years covering and investing in healthcare companies. He is also a non-executive director of BB Healthcare Investment Trust, listed on the London Stock Exchange, since Dec 2016. Randeep has been involved in a number of startup and early stage companies both personally and as an investor. He read medicine at the University of Cambridge and trained in the NHS as a vascular surgeon for eight years.

    • With over 18 years of senior management experience, Steven Couldwell was formerly Chief Operating Officer and Head of Global Biosurgery division at Sanofi, which has revenues of approximately $750m. He has a proven international track record in driving revenues and profit growth in the pharmaceutical, medical device and CRO industries. Steven was formerly Vice President and General Manager of Covance Laboratories Europe and worked for Smith & Nephew for almost 20 years in a number of roles including President Orthopaedics (Europe) and Senior VP Sales and Marketing for Smith & Nephew’s Advanced Wound Management business.

    • Jonathan was Group Finance Director of Consort Medical plc from September 2006 to December 2007 until he took up the position of Chief Executive Officer in December 2007. Prior to joining Consort Medical plc, Jonathan was global Head of Finance at Celltech Group plc and later Chief Financial Officer of Akubio Ltd, a Cambridge-based developer of instrumentation for the Life Sciences industry.

      Mr Glenn is a member of the Institute of Chartered Accountants in England and Wales.

    • Shervanthi Homer-Vanniasinkam graduated from Mysore University in India in 1981. She later became a Fellow of the Royal College of Surgeons of Edinburgh in 1989, and a Fellow of the Royal College of Surgeons of England in 1998.  She was appointed Consultant Vascular Surgeon at Leeds General Infirmary in 1995, a post she continues to hold. She also holds a number of appointments with various higher education and health trusts around the country including; Consultant Vascular Surgeon, The General Infirmary at Leeds, Clinical Sub-Dean, University of Leeds Medical School, Professor of Surgery (Founding), University of Warwick Medical School & University Hospitals Coventry and Warwickshire NHS Trust, Professor of Engineering and Surgery, University College London.


    • Corporate governance

      The Directors recognise the importance of sound corporate governance and have observed the principals of the UK Corporate Governance Code, to the extent that they consider them appropriate for the Group’s size.
      Internal Control
      The Board is responsible for maintaining a sound system of internal control. The Board’s measures are designed to manage, not eliminate risk, and such a system provides reasonable but not absolute assurance against material misstatement or loss. The board confirms that it has established the procedures necessary to implement the guidance “Internal Control Guidance for Directors on the Combined Code” (The Turnbull Report).
      Audit Committee
      The audit committee has primary responsibility for monitoring the quality of internal controls and ensuring that the financial performance of the Company is properly measured and reported on. It will receive and review reports from the company’s management and auditors relating to the interim and annual accounts and the accounting and internal control systems in use throughout the company. The audit committee will meet not less than twice in each financial year and will have unrestricted access to the company’s auditors.
      The Audit Committee consists of the following members:

      • Alan Miller (Chair)
      • Randeep Grewal
      • Jonathan Glenn  

      Remuneration Committee
      The remuneration committee will review the performance of the executive directors and make recommendations to the Board on matters relating to their remuneration and terms of service. The committee will also make recommendations to the Board on proposals for the granting of share options and other equity incentives pursuant to and share option scheme or equity incentive scheme in operation from time to time. The remuneration committee will meet as and when necessary. In exercising this role, the Directors shall have regard to the recommendations put forward in the QCA Guidelines.
      The Remuneration Committee consists of the following members:

      • Steven Couldwell (Chair)
      • Alan Miller
      • Randeep Grewal